Purpose In tumour, the imbalance between oxygen supply and demand leads to hypoxia, which represents a negative prognostic factor associated with aggressive tumour phenotype and therapy resistance. This review provides an overview of the use of positron emitter-labelled radiopharmaceutical used to image hypoxia in preclinical models of cancer. Methods A critical and comprehensive PubMed search was performed identifying articles related to PET imaging for hypoxia assessment in preclinical setting from January 2007 up to January 2017. Results We have considered and described a total of 54 original articles, exploring tumour-associated hypoxia in preclinical models. Results underlined the potential application together with the advantages and pitfalls of the use of PET in preclinical research. Multi-target imaging allowed to better define the relationship between hypoxia and other biological hallmarks of tumour; imaging of hypoxia was proved as a useful tool for lesions stratification and response prediction to radiotherapy; however, cutoff indexes were identified in few studies. Hypoxia PET showed remarkable tracer delivery limitations in the study of vascular disrupting agents but suggested the potential use of PET as a marker of response or resistance to antiangiogenics. Finally, the effect of anaesthesia on tracer kinetics and tumour oxygenation as well as perfusion dependency in tracer uptake should be carefully evaluated to avoid artefactual results. Conclusions Preclinical studies highlight the advantages and the limitations of the available hypoxia-radiotracers and their potential usefulness for the evaluation of treatments outcome and radiotherapy planning.
Introduction
Many solid tumours are characterized by the presence of areas with reduced oxygen tension (pO 2 ) resulting from a lack of equilibrium between the O 2 supply to the cell and the cellular O 2 consumption. It is well known that the high proliferation rate of cancer increases the energy demand causing several homeostatic effects including metabolic rewiring and production of a large but abnormal vascular network. Activation of angiogenesis produces a large although abnormal vascular network with vessels highly disorganized, presenting branch irregularities, shunts and a tortuous endothelium, thus increasing even more the energy unbalance. Indeed, abnormalities in blood supply determine fluctuations in regional tissue perfusion with temporal reduction of pO 2 values leading to ''acute hypoxia' ' . It has been demonstrated that acute hypoxia causes a decrease of oxidative metabolism, activating autophagy, that generates high levels of reactive oxygen species (ROS) and genomic instability. Altogether, these factors contribute to the selection of aggressive phenotypes which favour tumour resistance and diffusion [1, 2] . It was demonstrated that the level of tissue oxygenation influences tumour response to treatment, decreasing cell sensitivity to chemo and radiotherapy [1, 3, 4] . On the other hand, long-term hypoxia increases the probability of gene mutation and leads to the activation of pathways that regulate cell survival and apoptosis. It is well known that the activation of hypoxia-inducible factors (HIFs) is a key step in hypoxia-induced modifications of cell phenotype: it favours metabolic reprogramming, angiogenesis, remodelling of extracellular matrix and changes in cell motility and migration [5] . Finally, reduced pO 2 modifies tumour microenvironment also regulating cancer stem cells' selfrenewal and amplifying the pro-inflammatory phenotype of tumours, thus increasing tumour resistance. For these reasons, the identification and localization of hypoxic areas represent a unique resource tool for the in vivo study of tissue microenvironment in cancer and for the development of diagnostic/prognostic markers for patient stratification or early prediction of treatment efficacy [6] . Regional tissue hypoxia can be visualized using PET and different radiopharmaceuticals characterized by an oxygen-dependent mechanism of cellular uptake and retention. Preclinical studies have been performed in the last years to validate new hypoxic tracers or to set up methods for the early prediction of treatment efficacy or resistance. Finally, hypoxia tracers have been used in proof of concept studies to investigate novel hypoxia driven therapeutic strategies [2, 3] . Advantages of preclinical investigations are also the possibility to cross-validate imaging results, with postmortem molecular analysis on tissue homogenate or immunohistochemistry (IHC). Here, we describe, using a systematic revision of the literature of the last 10 years, the main preclinical findings obtained using radiopharmaceuticals and nuclear medicine techniques for the hypoxia imaging. With this review, we try to summarize the work done to develop and validate hypoxia radioligands and to understand their potential and added value for the improvement of clinical practice.
Literature acquisition
We performed a literature search using the electronic database PubMed. We identified original articles addressing the role of PET tracers for tumour hypoxia in preclinical setting published in the last 10 years (from 31 January 2007 to 31 January 2017). Reviews, book chapters and articles written in any other language than English were excluded. Preclinical has been used as limiting criteria and searching keywords included ''hypoxia'' or ''hypoxic'' and ''PET''. All manuscripts have been screened and those regarding human studies, chemical and physical or modelling analysis methods have been excluded. Moreover, manuscripts judged not strictly relevant for our purpose have been not considered, while manuscripts derived from selected bibliography and judged inherent with the stated purpose have been included. A total of 54 original papers based only on in vivo studies results have been considered. Additional references necessary to introduce hypoxia and cancer or previous description of hypoxia radiopharmaceuticals have been added together with studies identified from the reference list of the selected articles (Fig. 1 ). The majority of preclinical studies were focused on: (a) the relationship between regional tissue hypoxia identified with radiopharmaceuticals, and the specific molecular feature of tumour and (b) the use of hypoxia radiopharmaceuticals for response/ resistance prediction or treatment tailoring. The relevance and potential clinical translation of animal's studies has been also included and discussed.
Biological validation of hypoxia radiopharmaceuticals and its relationship with tumour phenotype
Imaging of tumour hypoxia with PET offers the great advantage to study reduced pO 2 in a non-invasive manner, giving 3-dimensional images of the whole lesion. Hypoxiadependent tracers belong to different chemical classes: nitroimidazole derivatives, radiolabelled copper ATSM complexes and carbonic anhydrase IX (CAIX) agents. The agents have been validated using IHC, pO 2 electrodes or oxygen challenges (see Challapalli for a detailed review of hypoxia radioligands and their mechanism of action) [3] . Validation and comparative studies with other cancer hallmarks published in the last 10 years are resumed in the following paragraph.
[ 18 F]-labelled nitroimidazole compounds
Under low oxygen condition, nitroimidazole undergoes nitro-reductive reactions and is transformed into reactive intermediate species. When pO 2 decreases below 10 mmHg, they are further transformed in radiolabelled reactive radical species that cannot be re-oxidized to the original compound and remain bound to different intracellular molecules (nucleic acid or protein). At the moment only for nitroimidazole derivatives, a clear cutoff value for oxygen-dependent trapping has been demonstrated. For this reason, this class of radiopharmaceuticals has been use to study at regional level the association between glycolysis, angiogenesis, cell proliferation, or other biological phenotypes of lesion with hypoxia (Table 1) . Validation studies were aimed to verify if and when tracer distribution overlapped those of molecular markers of hypoxia or to verify the artefactual presence of delivery effect in hypoxia images. 18 F]FMISO-PET and DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging) to evaluate tissue perfusion and to define the time frame of radioactivity uptake not affected by blood flow-dependent tracer delivery. In a preclinical model of prostate cancer, the syngeneic Dunning R3327-AT, PET-MRI combination clearly demonstrated that the initial phase of [ 18 F]FMISO accumulation was highly delivery dependent. Results of this study stress the concept that for each tracer a proper and accurate identification of the optimal time frame to be used in hypoxic study is highly recommended in order to avoid images contamination between hypoxia and delivery [7] .
In head and neck xenograft models, the uptake of [ 18 F]FMISO uptake and hypoxic fraction was found in tumours characterized by the ribbonlike pattern. When lesions with the more homogeneous distribution of hypoxia (patchy) were included in the analysis, the correlation although still present was weaker. Unfortunately, the low signal to noise ratio of [ 18 F]FMISO reduced its sensitivity in the detection of regional tissue hypoxia in small lesions, thus limiting its potential preclinical use for radio-therapeutic plan development because it precludes the evaluation of treatment efficacy in small early stage cancer [8] .
In osteosarcoma, a preclinical multi-molecular PET study which included [ 18 F]FMISO as radioligand gave relevant information to set up a stratification protocol to be further used for tailored treatment of patients. Osteosarcoma is the most common primary tumour of the bone [9] and [11] . [ 18 F]FMISO has been used also for the study of regional hypoxia in glioma models. High-grade gliomas are characterized by the presence of regions of low oxygen tension and the expression of several hypoxic markers including HIFs and carbonic anhydrase [12] . As previously stated, hypoxia enhanced proliferation, glycolysis and angiogenesis. Considering cell metabolism, a hypoxic environment gene responsible for glucose metabolism is upregulated by hypoxia-inducible factor-1 (HIF-1) which in turn targets metabolism-related proteins including the glucose transporter (Glut-1) and hexokinase-II (HK-II). For this reason, a certain number of studies were aimed to compare the distribution of hypoxic tissue defined using PET tracers with that of glycolysis, 18 F]FMISO (confirmed by PIMO) overlapped with that of Glut-1 indicating that hypoxia influences the expression of glucose transporter but not the general metabolic activity or proliferation of lesions [14] . Corroyer-Dulmont et al. studied the effect of tumour vascularization on regional tissue hypoxia. Using [
18 F]FMISO, the authors showed that the highly vascularized U87 glioma tumours were less hypoxic than the poorly vascularized U251 glioma [15] . Although [ 18 F]FMISO still represents a valuable biomarker of hypoxia, the intracellular uptake, its slow retention mechanism, the formation of metabolites and the requirement of a long time from injection to the intra-tumour distribution represent limits for its utilization, particularly when hypoxic region are small [3] . In fact, tumour/background (T/B) values resulting from the kinetic behaviour of [
18 F]FMISO are not always adequate for imaging. To overcome these limits, a large number of nitroimidazole derivatives have been radiolabelled and their kinetic behaviour evaluated at preclinical and in some cases at clinical level. . The simultaneous use of radioactive and nonradioactive staining agent EF5 for the assessment of tumour hypoxia using PET and immunohistochemistry has been evaluated in three different tumour models, i.e., prostate cancer (PC3), colon cancer (HCT116), and NSCL carcinoma (H460). Despite the potential interest, the authors showed that the concentrations of EF5 required for immunohistochemistry assays may affect the distribution of [ 18 F]EF5 in hypoxic cells in certain tumour types as observed in H460, thus limiting the use of this experimental protocol [23] . In addition, the radioligand [
18 F]EF5 was used to evaluate the modification of regional hypoxia occurring during tumour progression, studying head and neck tumour at two different stages of growth. The distribution of [
18 F]EF5 changed over time, but the concentration of the radioligand did not correlate with the rate of tumour growth (r = 0.503, p = 0.14) [25] These results were confirmed post-mortem using CAIX and HIF-1 as hypoxia markers and Glut-1 to estimate glycolysis [24] . 18 F]FMISO was influenced by nicotinamide or carbogen breathing. These last results reflect structure-specific differences in the rate of formation of the radical products, being faster for the first and slower for the latter, and the reversibility of intracellular hypoxic-dependent reduction reactions that were detectable only for [ 18 F]FMISO [29] .
Radiolabelled copper-ATSM complexes
Copper (II) diacetyl-bis (N4-methylthiosemicarbazone) (Cu-ATSM) was firstly examined as hypoxia-specific marker by Fujibayashi in 1997 [30] and widely applied as radiotracer after labelling with different copper radioisotopes ( 60 Cu, 61 Cu, 62 Cu, 64 Cu, and 67 Cu). The mechanism of oxygen-dependent trapping is not fully understood. Cu(II) in the absence of oxygen is irreversibly reduced to [32] . Similar findings were reported in head and neck, colon, prostate or breast xenograft models or in spontaneous canine tumours using different nitroimidazole derivatives or PIMO [33] [34] [35] [36] . However, other studies showed a complete overlapping between nitroimazoles and [
64 Cu]ATSM although in same case it was present only at later time after injection [36] . In 9L glioma and in two studies on FaDu xenograft model, the distribution of [ 64 Cu]ATSM was similar to that of nitroimidazoles [6, 13] (Fig. 2) . According to some authors, the heterogeneous behaviour of [
64 Cu]ATSM uptake may depend also by copper transports pumps present on cancer cell membranes [37] . Valtorta et al. [6] investigated [ 64 Cu]ATSM uptake and the expression of copper pumps markers (Ctr1 and ATP7B) in EMT6, PC3 and FaDu xenograft models. Results of the study showed that, in FaDu and EMT6, these pumps were mainly expressed around necrotic areas whereas in PC3 model Ctr1 and ATP7B were homogeneously distributed all over the lesions. However, the distribution of [ 64 64 Cu]ATSM accumulated in low vascularized regions of the tumour which displayed high levels of the stem cell-associated marker CD133 [38] . This finding was confirmed by the same group in the HT29 colon cancer mouse xenograft model. In addition, the areas of radioactivity distribution were also associated with an upregulation of pathways related with DNA repair. This last finding has important implications also for the use of [ 64 Cu]ATSM for therapy, since the upregulation of DNA repair and high levels of CD133, with poor prognosis and metastasis [39] . Results obtained with [
64 Cu]ATSM are summarized in Table 1 .
Carbonic anhydrase 9 (CAIX) agents
Another class of hypoxia imaging agents under evaluation targets CAIX (Carbonic anhydrase 9). CAIX is a member of the carbonic anhydrase family that has been proposed as the ''gold standard'' endogenous hypoxia-related cell marker. CAIX catalyses the reversible hydration of carbon di-oxide to carbonic acid. CAIX is one of the most highly HIF-1 induced genes and it is up-regulated under hypoxic conditions with pO 2 levels below 20 mmHg. tumour [40] . These negative results were also confirmed in a pilot study on renal cell carcinoma. Currently new molecules labelled with [ 68 Ga] that selectively targets CAIX are under investigation. Among these molecules, [ 68 Ga]CAIX displayed a higher tumour uptake and rapid renal excretion in the HCT116 colon cancer xenografts [41] .
Effect of anaesthesia on hypoxia radiopharmaceutical
Finally, a major issue on the kinetic of distribution of radiopharmaceutical is represented by anaesthesia administration, particularly concerning volatile agents. Anaesthesia and the relative gas carrier have been shown to affect the results of PET studies since they can influence radiotracer biodistribution and tumour uptake. In a study focused on the effect of anaesthesia on hypoxia radiopharmaceuticals, the impact of Isoflurane in oxygen (IO) Moreover, in mice anesthetized with KX the use of oxygen breathing instead of air reduced tumour to muscle ratios also when the anaesthesia was performed only for PET acquisition and not for the entire period of uptake [43] . The different effects of anaesthetics on mouse physiology and metabolism should be more extensively investigated because the results of these studies clearly indicate important kinetics and metabolic effects that should be carefully planned and control during the execution of the studies in order to avoid cofounding effect not associated with the study objective.
Emerging applications of hypoxia radiopharmaceuticals
An emerging application in pathology also if not related to tumour is the use of hypoxic tracers for the study of inflammatory diseases. [44] . The relationship between ROS levels, inflammation and hypoxia represents an important issue also for the study of cancer and future studies associating PET hypoxia radiopharmaceuticals with ROS or inflammatory markers are hardly suggested.
Use of hypoxia imaging for treatment tailoring
Tumour hypoxia is strongly related to poor outcome and radiotherapy resistance because of the involvement of oxygen in the fixation of radiation-induced DNA damage. Moreover, as previously stated, hypoxia induces metabolic reprogramming, transcription and activation of genes and pathways that regulate cell proliferation, survival and angiogenesis, leading to a decreased sensitivity to therapy [45] . In addition, hypoxic regions accumulate cancer stem cells (CSC) in the so-called ''hypoxic niche'' where CSC is self-renewal and transformed into more aggressive phenotypes [46, 47] (Table 2) . First, it can be used to stratify lesions on the basis of tissue hypoxia. Second, the identification of hypoxic regions enables to tailor radiotherapy plans on the basis of cells resistance. Finally, modification of tracer uptake can be used as surrogate marker to evaluate the efficacy of agents targeting or counteracting tissue hypoxia including hypoxic cells radiosensitizer or activated prodrugs (HAPs) [48] .
Radiotherapy
As already stated, hypoxia has a negative impact on radiotherapy efficacy. O 2 is able to fix DNA free radicals originating by ionizing radiation, thus precluding repairing system and making permanent the damage produced. For this reason, to kill hypoxic cells a three times higher doses of ionizing radiation than that used for normoxic cells are necessary [4] . For these reasons, hypoxia imaging was applied for the evaluation of tumour radiosensitivity and to explore the efficacy of increased or fractionated dose of radiations. In C3H mammary carcinoma model, [ 18- F]FAZA uptake values have been demonstrated to be prognostic of radiation efficacy allowing to predict animals' response on the basis of pretreatment hypoxic status, i.e., low hypoxic tumour (T/B mean = 1.56) and highly hypoxic tumours (T/B = 5.23). Less hypoxic tumours displayed at 90 days after treatment a better tumour control compared to more hypoxic tumours at a single dose of 55 Gy (230 kV X-rays). These results suggest a role for [ 18 F]FAZA to predict radiotherapy sensitivity and clinical outcome [49] . In the 9L glioma model, [ 18 F]FAZA uptake measured as T/B and evaluated at baseline was inversely correlated with clinical response to a 40 Gy dose (r = 0.67; p = 0.0012). In addition, threshold values of [ 18 F]FAZA T/B ratio of 1.7 discriminated radiosensitive versus radioresistant tumours. In the same study, carbogen treatment improved 9L glioma response to radiations. On the contrary, for the rhabdomyosarcoma tumours no correlation was found between accumulation of [ 18 F]FAZA and radiation outcome nor between carbogen inhalation and response to radiotherapy. This is probably explainable by the higher [ 18 F]FAZA T/B values observed in rhabdomyosarcoma that were above 1.7 in the majority of tumours. Nevertheless, an improvement of clinical outcome was observed only by increasing the radiation dose from 15 to 20 Gy [50] . Clinical studies showed that fractionated radiotherapy (FRT) is able to improve patients' outcome maximizing the radiation effect on cancer cells and minimizing the damages on healthy cells. One hypothesis is that FRT produces a transient increase of oxygenation, thus favouring the response to the next dose of radiations; this effect is known as reoxygenation [4] . For this reason, the use of PET and hypoxia radioligands represents a useful tool to set up fractionated therapy in different preclinical models of cancer and to verify the FRTinduced tissue reoxygenation. Busk On the contrary, high intra-tumour variability was obtained when normal background tissues radioactivity concentration values were used to normalize data. In addition, radioactivity distribution within the tumour was stable indicating that [ 18 F]FAZA was able to depict the same intra-tumour hypoxic regions and borders also if evaluated at different time frames. Concerning the reoxygenation effect, the authors showed that the administration of four radioactivity fractions failed to modify tissue oxygenation. A trend of reducing [
18 F]FAZA uptake values was observed for the ten fractions protocol. Furthermore, in vivo imaging allowed to detect a high intra-individual and time-dependent variability in tumour response that is difficult to detect by post-mortem IHC analysis if not using a larger number of animals [51] . In another study on lung A549 lung cancer xenograft, [ 18 F]EF5 uptake was able to predict response to a single fraction of radiotherapy, also confirming the role of hypoxic status for response prediction and dose adjustment [52] . Indeed, stratification of tumour on the basis of baseline [
18 F]EF5 uptake (positive or negative uptake of [ 18 F]EF5 using a T/M ratio of 2.5) was able to discriminate responder from non-responder to single or fractionated therapy. The authors observed that a single administration of 10 Gy determined a reduction of tumour volume in [ 18 F]EF5-negative tumours which were significantly different from [
18 F]EF5-positive tumours. No significant differences between positive and negative [ 18 F]EF5 tumours were found using other doses of radiotherapy, fractionated or not; however, it was possible to observe a trend towards a major effect of FRT in tumours defined as [ 18 F]EF5 negative [52] .
Association of hypoxia activating prodrug or hypoxic cytotoxin to radiotherapy
Another potential strategy to overcome tumour resistance induced by hypoxia is the use of drugs able to increase the effect of radiotherapy in hypoxic regions (radiosensitizers) or to kill tumour cells on the basis of their pO2 content (hypoxic cytotoxins). These molecules are prodrugs, deactivated or masked cytotoxins that are activated after biotransformation by endogenous human cellular oxidoreductases. This activation step is catalysed by different enzymes, one-electron and two-electron oxidoreductases, and it is inhibited in the presence of oxygen. The one-or two electron reductases, such as cytochrome P450 reductase, add an electron to the prodrug. In the presence of oxygen, the radical electron of the prodrug is transferred to molecular oxygen, thus regenerating the initial prodrug. In the absence of oxygen, the radical electron present in the pro-drug is able to accumulate in cell, thus producing cytotoxicity directly or after transformation in other products. For this reason, these drugs are also defined as hypoxia-activated prodrugs (HAP) [48] . On the basis of their mechanism of action, it is intuitive that the use of hypoxia-PET as biomarker for pre-therapy selection of patients is mandatory. In addition, hypoxia imaging should be used from the early stage of preclinical development.
Hypoxia activated prodrugs
Hypoxic cells radiosensitizers like 2-nitroimidazole (misonidazole and metronidazole) analogues which undergo a hypoxia-dependent nitro-reduction are structural analogue of the radiopharmaceuticals (from whom they were designed) and were proposed in the early sixties by Adam and Cook. The original idea was to use electronaffine chemical drugs to mimic O 2 , as radiosensitizer. During hypoxia, they are selectively reduced, forming DNA-damaging free radicals [53] . These drugs, particularly misonidazole, showed some anti-tumour efficacy also in clinical setting when combined with ionizing radiation [48] . [ 18 F]FAZA-PET has been validated as a tool to assess and predict the effect of nimorazole radiosensitizers and radiotherapy. Radiotherapy with nimorazole was superior to radiotherapy alone when rhabdomyosarcoma tumours were stratified on the basis of their pre-treatment hypoxic status according to median [ 18 F]FAZA T/B ratio. When all tumours were considered, irradiation with 20 Gy determined a comparable effect to irradiation with 20 Gy plus nimorazole. When animals were stratified on the basis of pre-treatment [ 18 F]FAZA uptake (T/B cutoff = 2.72), RT plus nimorazole was superior to RT alone for ''more hypoxic'' tumours. On the contrary, in a 9L glioma model, despite the higher benefit of nimorazole and radiotherapy combination, [ 18 F]FAZA uptake was not predictive of clinical response [54] . Taken together, the results of these studies indicated that hypoxia PET might be a useful tool also in clinical practice for tumour stratification and treatment tailoring on the basis the hypoxic status of lesions.
Stereotactic ablative radiation therapy (SABR) is an imaging guided system able to deliver high radiation doses to the target tissue without damaging normal structures. SABR protocols deliver higher dose of radiations in comparison with standard radiotherapy, dividing the total dose in few fractions [55] . As for FRT, one of the potential biological effects of SABR is to improve tumour oxygenation, thus enhancing the sensitivity to the next doses. Hypoxic tracers were also tested in the setting of the optimal schedule of SABR. Song et al. showed in a syngeneic Lewis model of lung carcinoma a decrease of [ 18- F]FMISO uptake 6 h after irradiation (15 Gy) that could be induced by tumour reoxygenation. However, post-mortem analysis using the perfusion agent Hoechst 33342 and CD31 staining showed a rapid and transient vascular collapse and reduction in intra-tumour perfusion. Vascular damage could reduce [ 18 F]FMISO delivery, thus producing artefactual information of the effects of radiation on lesion oxygenation [56] . In this case, hypoxia imaging can be used only if full compartmental kinetic analysis is applied to differentiate metabolic effect from delivery.
The potential advantage of [ 18 F]EF5 imaging in tumour selection and response prediction to the cytotoxic benzotriazine di-oxide HAP SN30000 plus radiotherapy has been assessed in a model of lung carcinoma (H460). Results of the study showed that [ 18 F]EF5 uptake correlated with tumour size and that post-treatment reduction was related with baseline tumour volume and hypoxia. The effect on tumour growth appeared higher with SN30000 plus radiotherapy. Indeed, combination treatment decreased [ 18 F]EF5 uptake in all tumours except one, with a decrement of mean standardized uptake values (SUV mean ) ranging from 9 to 31%. Moreover, authors observed a negative correlation between SUV mean at the baseline and treatment-induced change in SUV mean (r = -0.88; p \ 0.0001) [26] . The HAP SN30000 is also intracellularly activated by one-electron reductase, which is a heterogeneous group of enzymes that is involved also in the processing of 2-nitroimidazole. Interestingly Wang et al. demonstrated that EF5, SN30000 and other benzotriazine di-oxide HAPs were activated by the reductase [57, 58] . For this reason, Hunter et al. [48] proposed the use of 2-nitroimidazole PET imaging agents not only to image hypoxia but also to verify the activity of the one-electron reductase that specifically processes this class of HAPs.
Evofosfamide (TH-302) is a 2-nitroimidazole hypoxia prodrug showing promising therapeutic effects both as monotherapy or in combination to radiation. TH-302 efficacy was studied using the third-generation hypoxia radiopharmaceutical [ 18 F]flortanidazole (HX4) as imaging marker [59] . In the study, TH-302 was evaluated in two hypoxic xenograft models and the authors demonstrated that the use of HAP endorsed the effect of radiotherapy in both R1 rhabdomyosarcoma and H460 lung cancer and that [ 18 F]HX4 was a useful tool to monitor its effect. In addition, the tumour hypoxic fraction measured in vivo with [ 18 F]HX4 PET influenced the effect of TH-302 in slowing tumour growth. Indeed, the authors observed that the hypoxic fraction at the baseline was associated with treatment outcome expressed as time to increase the tumour volume: TH-302-treated tumours showed an increase in the time in which tumour reached four times its start volume (T4xSV) and the response correlated to the hypoxic fraction at onset.
Hypoxia cytotoxins
Targeting hypoxic cells before radiotherapy with hypoxiaselective cytotoxins, it is able to control metastatic disease when used as neoadjuvant treatment. Equi-toxic doses of the two nitro-imidazoles NLCQ-1 and RB6145 and the aromatic-N-oxide tirapazamine (TPZ) were administered to animals bearing KHT sarcoma tumours, 3-6 days post-radiotherapy. The authors showed that all treatments induced a significant improvement of lung disease, with NLCQ-1 being the most efficacious, particularly in controlling metastasis induced by the primary tumour, as revealed using [ 18 F]FDG-PET to visualize tumour dissemination at 20-day post-therapy [60] . In EMT6 model, using [ 18 F]FAZA to image hypoxia, TPZ given as a single agent (CHT) had no significant effect on tumour growth independently from the hypoxic status of lesions. However, when associated with radiotherapy, TPZ showed an additive effect on tumour growth delay in hypoxic tumours classified on the basis of [
18 F]FAZA T/B cutoff values higher than 1.97 at baseline [61] . These data on the use of hypoxia-selective cytotoxins as ''cooperative therapy'' demonstrated again that PET and hypoxia radiopharmaceuticals could be helpful to better predict and tailor treatment.
Hypoxia based radiometabolic therapy
The radioligand [
64 Cu]ATSM owns the unique property to be an imaging agent accumulating in hypoxic areas and at the same time exerting a therapeutic effect due to its bdecay and electron capture. It has been postulated and proved in colon cancer xenograft that [
64 Cu]ATSM preferentially accumulated in intra-tumour regions with high density of the stem marker CD133, thus reducing the positive cell population and its metastatic potential [38] . More recently, the same authors using the HT29 colon carcinoma model demonstrated that the regions of [ 64- Cu]ATSM uptake characterized by CD133 expression and DNA repair would benefit by the association of NA (nucleic acid) antimetabolite to [ 64 Cu]ATSM (37 MBq) therapy [39] . A method to reduce Cu accumulation in nontarget organs and to reduce [
64 Cu]Copper-associated radiotoxicity has been proposed by Yoshii et al. who evaluated the effect of penicillamine pretreatment on the distribution of [ 64 Cu]ATSM in a HT29 colon cancer xenograft [62] . Penicillamine is a heavy-metal chelating agent which is often used to treat intoxication by heavy metals. For this reason, the authors investigated whether the administration of penicillamine before [
64 Cu]ATSM injection could be effective to reduce 64 Cu accumulation in non-target organs such as liver and thus radiation exposure without affecting [ 64 Cu]ATSM uptake in tumours. Results of the study showed that penicillamine was able to decrease liver uptake, without affecting that of tumour independently if [ 64 Cu]ATSM was administered at tracer or therapeutic doses. Furthermore, the co-administration of laxative reduced the 64 Cu accumulation in the large intestine, although the duration of penicillamine effect was slightly reduced.
Anti-angiogenic drugs
As previously stated, the decrease in partial pressure of oxygen (pO 2 ) is also related with modifications in vascular network during tumour growth. Vascular system is a wellestablished therapeutic target for cancer. Two different Clin Transl Imaging (2017) 5:407-425 419 pharmacological classes of drugs have been developed so far and applied to different types of cancer: anti-angiogenic agents that hinder new vessels development and vascular disrupting agents (VDA) that act on established blood vessels. Anti-angiogenic drugs are antibody or small molecules that target the vascular endothelial growth factor (VEGF); their activity may be direct, blocking VEGF ligand or receptors, or indirect, through the inhibition of VEGF-dependent tyrosine kinases (TKI). Conversely, the mechanism of VDA implies the disruption of established blood vessels. Both anti-angiogenic and vascular disrupting agents have been proposed in association with radio-or chemotherapy because of their potential role on tumour vascularization and metabolism. Either VDA or anti-angiogenesis determines a cytostatic rather than a cytotoxic effect. In addition, these drugs induce important although distinct effects on cell metabolism and acting on vessels might affect cell oxygenation. For their mechanism of action, hypoxia imaging represents a unique tool, particularly to detect modification induced by treatment on cell composition and phenotype within lesion (Fig. 3) . Table 2 summarizes the preclinical applications of hypoxia radioligands in monitoring anti-angiogenic treatments in different tumour models.
Vascular disrupting agents (VDA)
The effect of VEGF121/rGel was evaluated using a multimolecular PET imaging approach [63] . VEGF121/rGel is a fusion protein of VEGF121 and the plant toxin gelonin (rGel) that acts as a VDA. DMXAA also known as Vadimezan or ASA404 is a VDA which showed some promising effects in clinical trials on lung and prostate cancer. This drug, whose therapeutic targets and relative anticancer mechanism are not fully understood, induces cell apoptosis and decreases perfusion in existing vessels [64] . In HT29 colon cancer xenografts, [ 18 F]FMISO has been used to assess DMXAA effect on tumour oxygenation comparing PET images with IHC staining for hypoxia and perfusion markers, performed at baseline and after therapy. DMXAA administration resulted in a marked reduction in the 18 F]FMISO uptake after DMXAA could reflect modification in tracer delivery caused by vascular disruption [65] .
Tyrosine kinase (TK) inhibitors
The effect of the TK inhibitor Sorafenib on regional tumour hypoxia was also evaluated with [ 18 F]FMISO in a preclinical model of renal carcinoma based on A498 cells. Sorafenib administration did not modify tumour volume but induced lesion enrichment of hypoxic cells at early time after the beginning of treatment, as shown by the presence of large tumour areas of [ 18 F]FMISO uptake, confirmed also by hypoxic IHC markers. The rapid increase of [ 18 F]FMISO uptake was described as an index of tumour starvation occurring after anti-angiogenic treatment [66] . Sunitinib represents a type I TKI which acts directly on tumour cells and on tumour microenvironment. Anti-angiogenic treatments have been proposed in glioma to improve vasculature organization and tumour oxygenation. The effects of Sunitinib on tumour hypoxia were evaluated in two different glioma models using a multimodal imaging approach based on the combined use of [ 18 [69] . Sunitinib treatment has been tested also in breast cancer models where is able to delay tumour growth. In a multi-molecular imaging PET study, Theze and colleagues studied the effect of Sunitinib on an immunocompetent, Luminal B (HER2-positive) Mammary Carcinoma model (MMTV-PyMT mouse 18 F]FDG uptake, as indicated by the lack of modifications in intra-tumour radioactivity concentration observed in treated compared to non-treated animals. [ 18 F]FMISO-PET showed a decrease of hypoxia in treated animals. In addition, a reduction of vascular volume, a marked increase of cell apoptosis and a reduction of hypoxia induced factor 1 alpha (HIF-1 alpha) expression were also observed in post-mortem ICH analysis. However, the occurrence of lung metastases was not reduced by the drug [70] . Inhibition of epidermal growth factor receptor (EGFR) with the TKI Erlotinib is often associated with decrease expression of the downstream markers of hypoxia, HIF-1a and VEGF. Indeed, [ 18 F]FMISO uptake decreased as consequence of Erlotinib administration [71] .
Anti-VEGF
Among the anti-angiogenic compounds, Bevacizumab is an antibody against VEGF able to inhibit VEGF. The exact mechanism of action of bevacizumab has not been fully understood but it is widely known that it leads to a normalization of tumour vessels, thereby increasing delivery of cytotoxic agents to the tumour and thus improving treatment efficacy. However, repeated treatment with antiangiogenic agents affects cell metabolism and induces the activation of glycolysis genes [72, 73] F]FMISO uptake, followed by a progressive decrement. At the end of the study, treated animals showed uptake values lower than control animals. These results were confirmed by pimonidazole IHC staining. Post-mortem IHC performed at the end of the study showed in treated animals a reduction of tumour vascularization but higher values of Glut-1 and CAIX [72] . In addition, the level of Bevacizumab in the blood of the mice was inversely correlated to CAIX expression, suggesting a stronger effect with longer and higher dose exposition. CAIX can be induced also in mild hypoxic condition, thanks to the activity of PI3K pathway. According to the authors, bevacizumab treatment increases hypoxia and glycolysis to levels above those observed in non-treated, which could not be detected by [ 18 F]FMISO-PET or pimonidazole staining [74] . Whether the differences observed between IHC and PET can be explained with a reduced vascularization which can affect tracer accessibility remains to be established. Despite the different sensitivity, in bevacizumab-treated animals, at the end of the study, [ 18 F]FDG and [ 18 F]FMISO showed values above those measured before the beginning of the treatment. In conclusion, the results of the study clearly indicate that Bevacizumab switches cells to a more glycolytic and hypoxic phenotype in comparison with pretreatment conditions [72] . The effect of the anti-angiogenic antibody Bevacizumab has been evaluated also in two models of ovarian cancer characterized by a different glycolytic phenotype using [ 18 18 F]FAZA uptake) only at late time. Therefore, the cytostatic effect of Bevacizumab was accompanied by the selection of the more aggressive population of cells which would proliferate and generate therapy resistance and recurrence. Moreover, the authors developed xenografts from excised tumours which were previously treated or not with Bevacizumab and they observed that cell tumours from Bevacizumab-treated animals showed rate of growth higher than that of tumour cell deriving from control animals; this confirmed that anti-angiogenic treatment has worked to select a more aggressive phenotype (Fig. 3) .
Mitochondrial complex I inhibitor
Mitochondrial complex I inhibitors are experimental drugs able to reduce cell hypoxia and inhibits hypoxia-related genes. BAY 87-2243 is a molecule owning to this new class of compound able to modulate the hypoxia-induced activity of the HIF-1a pathway and hypoxia-induced gene activation. Hypoxia imaging represents a unique tool to test if the effect on hypoxia-related gene is produced downstream or it is associated with a reduction of cell hypoxia. 
Conclusions
Results of the studies of the last 10 years show how preclinical PET represents a useful tool not only for tracer characterization but also to provide proof of concept results for a further translation of hypoxia radiopharmaceuticals into clinical practice. Multi-target preclinical studies indicated how hypoxia/glycolysis and tumour proliferation are differently associated with each other depending on tumour phenotype or illness progression. Moreover, as shown for osteosarcoma, PET imaging may be used for tumour phenotyping, representing the rationale for a further clinical development of imaging biomarker during drug design (Tables 1, 2 ). Finally, new potential application on inflammatory disorders is under evaluation and this might be of interest for a better understanding of the relationship between hypoxia and inflammation ( Table 1) . A large number of studies were focused on radiotherapy ( Table 2) . The results showed how hypoxia PET allows lesions stratification. Unfortunately, cutoff values have been defined only in a limited number of studies. Despite the interest, a limit to the diffusion of this type of studies is represented by the availability of preclinical radiotherapy devices dedicated to small animals. Hypoxia imaging provides an added value for radio-sensitizer to evaluate post-treatment tumour oxygenation and represents a potential biomarker for patient inclusion in clinical trial. Considering VDA, hypoxia imaging is limited by treatment-related modifications in radiopharmaceutical delivery, thus causing artefactual results. Studies on antiangiogenesis showed the potential use of hypoxia-PET not only to monitor efficacy but also for the development of drug-induced resistance. [ 64 Cu]ATSM studies showed how tumour retention of radioligands can be linked to biological properties other than hypoxia, including impairment of mitochondrial electron transport chain or pH. However, this could represent an advantage for radiotherapy. Finally, the type and protocol for anaesthesia should be carefully validated and defined to avoid artefactual results as clearly demonstrated in some studies designed for this purpose (Table 1) . Overall, limits of the studies are represented by the large number of radiopharmaceuticals, owing to the same chemical class but presenting relevant differences in the kinetic of distribution and intracellular reductive mechanism. These tracers have been cross validated only in a limited number of researches. This aspect, which is common also to clinical studies, reduces multi-laboratory studies and favours researches duplication and clustering of knowledge.
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